Literature DB >> 20044050

The effect of routine vaccination on invasive pneumococcal infections in Canadian children, Immunization Monitoring Program, Active 2000-2007.

Julie A Bettinger1, David W Scheifele, James D Kellner, Scott A Halperin, Wendy Vaudry, Barbara Law, Gregory Tyrrell.   

Abstract

Active surveillance was conducted by the 12 centers of the Canadian Immunization Monitoring Program, Active from 2000-2007 in children 16 years of age and younger to determine the influence of 7-valent pneumococcal conjugate immunization programs on the prevalence, serotype and antibiotic resistance patterns of invasive pneumococcal disease (IPD) caused by Streptococcus pneumoniae. The absolute number of reported IPD cases decreased 48% (p<0.01) over the 8-year period and 56% (p<0.01) in children 0-4 years of age. The absolute number of reported IPD cases caused by serotypes in the conjugate vaccine decreased 87.5% (p<0.01) overall and 92% (p<0.01) in children 0-4 years. Although 6 non-vaccine serotypes increased over time, only serotype 19A increased significantly (p<0.01). Overall, the proportion of penicillin resistant isolates remained unchanged at 17%. Cefotaxime/ceftriaxone resistance remained unchanged at 2% of isolates annually. Universal pneumococcal conjugate infant immunization programs have dramatically decreased cases of invasive pneumococcal disease. Copyright 2009 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20044050     DOI: 10.1016/j.vaccine.2009.12.026

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  32 in total

Review 1.  Serotype replacement in disease after pneumococcal vaccination.

Authors:  Daniel M Weinberger; Richard Malley; Marc Lipsitch
Journal:  Lancet       Date:  2011-04-12       Impact factor: 79.321

2.  Optimizing Canadian public immunization programs: a prescription for action.

Authors:  David W Scheifele; Monika Naus; Natasha S Crowcroft; Simon Dobson; Scott A Halperin; Gordean Bjornson
Journal:  Can J Public Health       Date:  2011 May-Jun

Review 3.  The impact of new vaccine introduction on immunization and health systems: a review of the published literature.

Authors:  Terri B Hyde; Holly Dentz; Susan A Wang; Helen E Burchett; Sandra Mounier-Jack; Carsten F Mantel
Journal:  Vaccine       Date:  2012-08-29       Impact factor: 3.641

4.  Update on the Use of Conjugate Pneumococcal Vaccines in Childhood: An Advisory Committee Statement (ACS) National Advisory Committee on Immunization (NACI).

Authors:  Shalini Desai; Allison McGeer; Caroline Quach-Thanh; Denise Elliott
Journal:  Can Commun Dis Rep       Date:  2010-11-23

5.  Long-term trends in invasive pneumococcal disease in Manitoba, Canada.

Authors:  Salaheddin M Mahmud; Hasantha Sinnock; Luiz C Mostaço-Guidolin; Gurpreet Pabla; Aleksandra K Wierzbowski; Songul Bozat-Emre
Journal:  Hum Vaccin Immunother       Date:  2017-05-11       Impact factor: 3.452

6.  Changing trends in serotype distribution and antimicrobial susceptibility of Streptococcus pneumoniae causing invasive diseases in Central Thailand, 2009-2012.

Authors:  Wanatpreeya Phongsamart; Somporn Srifeungfung; Tanittha Chatsuwan; Pongpun Nunthapisud; Vipa Treerauthaweeraphong; Pimpha Rungnobhakhun; Sirintip Sricharoenchai; Kulkanya Chokephaibulkit
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

7.  Update on the success of the pneumococcal conjugate vaccine.

Authors:  Jd Kellner
Journal:  Paediatr Child Health       Date:  2011-04       Impact factor: 2.253

8.  Serotypes and genotypes of invasive Streptococcus pneumoniae before and after PCV10 implementation in southern Brazil.

Authors:  Juliana Caierão; Paulina Hawkins; Fernando Hayashi Sant'anna; Gabriela Rosa da Cunha; Pedro Alves d'Azevedo; Lesley McGee; Cícero Dias
Journal:  PLoS One       Date:  2014-10-30       Impact factor: 3.240

9.  Controlled inflammatory responses in the lungs are associated with protection elicited by a pneumococcal surface protein A-based vaccine against a lethal respiratory challenge with Streptococcus pneumoniae in mice.

Authors:  Fernanda A Lima; Daniela M Ferreira; Adriana T Moreno; Patrícia C D Ferreira; Giovana M P Palma; Jorge M C Ferreira; Isaias Raw; Eliane N Miyaji; Paulo L Ho; Maria Leonor S Oliveira
Journal:  Clin Vaccine Immunol       Date:  2012-07-03

10.  Combination of pneumococcal surface protein A (PspA) with whole cell pertussis vaccine increases protection against pneumococcal challenge in mice.

Authors:  Maria Leonor S Oliveira; Eliane N Miyaji; Daniela M Ferreira; Adriana T Moreno; Patricia C D Ferreira; Fernanda A Lima; Fernanda L Santos; Maria Aparecida Sakauchi; Célia S Takata; Hisako G Higashi; Isaías Raw; Flavia S Kubrusly; Paulo L Ho
Journal:  PLoS One       Date:  2010-05-27       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.